Skip to main content
Premium Trial:

Request an Annual Quote

GenapSys: Jason Myers, Hesaam Esfandyarpour

GenapSys has named Jason Myers CEO, effective Feb. 15, 2021, replacing founder Hesaam Esfandyarpour. Myers will also join the board of directors. 

Myers comes to GenapSys from Invitae, where he was president of oncology. Prior to that, he was president and CEO of ArcherDx, which he also cofounded, until Invitae acquired the company last October. He also previously held positions at Ion Torrent, and holds a doctorate molecular pharmacology from Stanford University. Myers will continue to serve on Invitae's board of directors.

Esfandyarpour, who served as CEO since 2010, will remain as GenapSys' chairman. 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.